XXXXX for Intermittent Prevention of Menstrual Migraine

Summary:

Approximately 470 participants will be randomized and assigned treatment in the double blind treatment period of the study. Participants will be randomized in a 1:1 ratio across 2 treatment groups: XXXXX 75 mg dosed daily for 7 days (PMP) or matching placebo.

Type of study (PIC, Recruiting):  

Recruiting

Commercial Study - Site Identification form required to be completed, please find Site ID form uploaded to study documents link below. 

If you have been contacted directly by sponsor/CRO to take part in this study, you are NOT required to complete the NIHR Site Identification form.  Please confirm by return email that you are in direct contact with sponsor/CRO and are completing their questionnaire.  If you require any support with this process, please let us know and we would be happy to discuss. 

Recruitment Duration: 

10/10/2024 to 22/04/2026

Practice Activity: 

Please see part B

Practice Eligibility Criteria: 

GP Practices in the East Midlands

Practice Target: 

To be confirmed

Is this Study Applicable for RSI Scheme?  

Yes, applicable for RSI scheme 

Research Costs: 

Commercial research studies follow a national tariff guideline. Click here for more information on the tariff or download the tariff by clicking here